BRAF-Mutant Transcriptional Subtypes Predict Outcome of Combined BRAF, MEK, and EGFR Blockade with Dabrafenib, Trametinib, and Panitumumab in Patients with Colorectal Cancer

PURPOSE: The influence of the transcriptional and immunologic context of mutations on therapeutic outcomes with targeted therapy in cancer has not been well defined. BRAF V600E-mutant (BM) colorectal cancer comprises two main transcriptional subtypes, BM1 and BM2. We sought to determine the impact o...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Clin Cancer Res
Hauptverfasser: Middleton, Gary, Yang, Yiqun, Campbell, Catarina D., André, Thierry, Atreya, Chloe E., Schellens, Jan H.M., Yoshino, Takayuki, Bendell, Johanna C., Hollebecque, Antoine, McRee, Autumn J., Siena, Salvatore, Gordon, Michael S., Tabernero, Josep, Yaeger, Rona, O’Dwyer, Peter J., De Vos, Filip, Van Cutsem, Eric, Millholland, John M., Brase, Jan C., Rangwala, Fatima, Gasal, Eduard, Corcoran, Ryan B.
Format: Artigo
Sprache:Inglês
Veröffentlicht: 2020
Schlagworte:
Article
Online Zugang:https://ncbi.nlm.nih.gov/pmc/articles/PMC8194012/
https://ncbi.nlm.nih.gov/pubmed/32047001
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1078-0432.CCR-19-3579
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!

Ähnliche Einträge